Compounds > efavirenz

efavirenz and Drug Abuse, Intravenous

efavirenz has been researched along with Drug Abuse, Intravenous in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Abidin, ZZ; Chidambaram, SK; Fahrni, ML; Lazzarino, AI; Misran, NFL1
León, E; Lozano de León-Naranjo, F; Pérez-Rivera, AÁ; Sáez, P1
Chang, CM; Chen, HT; Chu, WL; Hsieh, LY; Ko, NY; Ko, WC; Lauderale, TL; Lee, HC; Lee, NY; Lin, CC; Lo, HJ; Tseng, FC; Wang, YL; Wu, CJ; Yang, YL1
Chan, K; Kozai, T; Lima, VD; Montaner, JS; Nosyk, B; Wood, E; Zhang, W1
Parienti, JJ1
Hirschel, B1
Clarke, SM; Mulcahy, FM1
Bernasconi, E; Bucher, HC; Flepp, M; Hirschel, B; Ledergerber, B; Telenti, A; Wagels, T; Zellweger, C1

Reviews

1 review(s) available for efavirenz and Drug Abuse, Intravenous

ArticleYear
Efavirenz therapy in drug users.
    HIV medicine, 2000, Volume: 1 Suppl 1

    Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Methadone; Oxazines; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous; Substance-Related Disorders

2000

Other Studies

7 other study(ies) available for efavirenz and Drug Abuse, Intravenous

ArticleYear
Clinical predictors of efavirenz-based regimen treatment durability: A two-year case-control study of antiretroviral-naïve patients.
    Journal of infection and public health, 2023, Volume: 16, Issue:1

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Opportunistic Infections; Retrospective Studies; Substance Abuse, Intravenous; Treatment Outcome; Viral Load

2023
[HIV infected women with intense bone and muscular pain and general weakness].
    Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29, Issue:4

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Muscle Weakness; Musculoskeletal Diseases; Organophosphonates; Osteomalacia; Pain; Radionuclide Imaging; Radiopharmaceuticals; Substance Abuse, Intravenous; Technetium Tc 99m Medronate; Tenofovir

2011
Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Benzoxazines; Candida; Candidiasis, Oral; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Female; Fluconazole; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oropharynx; Outpatients; Prospective Studies; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous; Taiwan; Young Adult

2012
Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
    AIDS (London, England), 2012, Jul-31, Volume: 26, Issue:12

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome; Viral Load

2012
Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy.
    AIDS (London, England), 2002, Oct-18, Volume: 16, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous

2002
Substitution for protease inhibitors in HIV therapy.
    The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Patient Dropouts; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous

2003
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort.
    AIDS (London, England), 2002, Feb-15, Volume: 16, Issue:3

    Topics: Adult; Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Tolerance; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Substance Abuse, Intravenous; Switzerland

2002